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Douglas B. Young3, Teresa Cortes4, Dijana Matak-Vinkovic2, Colin W. Levy1, 
Stephen E. J. Rigby1, David Leys1, Chris Abell2 & Andrew W. Munro1
Mycobacterium tuberculosis (Mtb) causes the disease tuberculosis (TB). The virulent Mtb H37Rv 
strain encodes 20 cytochrome P450 (CYP) enzymes, many of which are implicated in Mtb survival 
and pathogenicity in the human host. Bioinformatics analysis revealed that CYP144A1 is retained 
exclusively within the Mycobacterium genus, particularly in species causing human and animal disease. 
Transcriptomic annotation revealed two possible CYP144A1 start codons, leading to expression of (i) 
a “full-length” 434 amino acid version (CYP144A1-FLV) and (ii) a “truncated” 404 amino acid version 
(CYP144A1-TRV). Computational analysis predicted that the extended N-terminal region of CYP144A1-
FLV is largely unstructured. CYP144A1 FLV and TRV forms were purified in heme-bound states. Mass 
spectrometry confirmed production of intact, His6-tagged forms of CYP144A1-FLV and -TRV, with 
EPR demonstrating cysteine thiolate coordination of heme iron in both cases. Hydrodynamic analysis 
indicated that both CYP144A1 forms are monomeric. CYP144A1-TRV was crystallized and the first 
structure of a CYP144 family P450 protein determined. CYP144A1-TRV has an open structure primed for 
substrate binding, with a large active site cavity. Our data provide the first evidence that Mtb produces 
two different forms of CYP144A1 from alternative transcripts, with CYP144A1-TRV generated from a 
leaderless transcript lacking a 5′-untranslated region and Shine-Dalgarno ribosome binding site.
Mycobacterium tuberculosis (Mtb) is the causative agent for tuberculosis (TB), a chronic, infectious human dis-
ease that is responsible for the death of more than 1.5 million people annually. Major efforts have been made in 
recent years to produce new, effective antibiotics against Mtb1,2. New anti-TB drugs are desperately needed as a 
result of the emergence of drug-, multidrug- and extensively drug-resistant strains of Mtb, which have arisen as 
a consequence of factors including poor patient compliance with drug regimens. The “deadly synergy” between 
Mtb and the human immune deficiency virus (HIV) has also been an important factor contributing to the spread 
of TB and increase in human morbidity3. The best studied form of Mtb is H37Rv4, a virulent strain which has 20 
genes encoding cytochrome P450 enzymes (P450s or CYPs)1,4,5. P450 monooxygenase enzymes are hemoproteins 
that typically catalyse the activation of molecular oxygen and the insertion of an atom of oxygen into a substrate 
bound close to the heme iron6. The high proportion of the Mtb genome dedicated to P450s implicates these 
enzymes in multiple important biochemical functions, and the anticipation that Mtb P450s may be involved in 
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the pathogenicity and survival of the bacterium in the host has led to a focus of drug discovery efforts on Mtb 
P450s for new anti-TB compounds7–9. Characterization of P450 enzymes from Mtb has provided evidence for 
their involvement in the metabolism of lipids and sterol molecules, the oxidative modification of respiratory 
menaquinone and the production of cyclic dipeptide secondary metabolites1,7,10–14.
Currently, six of the Mtb P450s have been crystallized and structures of these enzymes have been determined 
in both ligand-free and various substrate/inhibitor-bound forms7,9,11,13,15–17. Physiological roles have been identi-
fied for CYP142A1 and CYP125A1 as host cholesterol catabolizing enzymes17,18, and also for CYP124A1 in sterol 
and/or branched chain fatty acid oxidation11. CYP132A1 was also proposed to be involved in fatty acid metab-
olism based on its similarity to eukaryotic CYP4 family fatty acid hydroxylases19. CYP51B1 is related to eukary-
otic sterol 14α -demethylases (with fungal CYP51 enzymes being important targets for azole class drugs), while 
CYP121A1 is involved in secondary metabolite synthesis, catalysing the oxidative crosslinking of the aromatic 
side chains of the cyclic dipeptide cyclo-L-Tyr-L-Tyr (cYY) to form the product mycocyclosin. The CYP121A1 
gene was reported to be essential for Mtb viability, although the function of mycocyclosin remains unclear13,15,20. 
In view of the important roles demonstrated for the aforementioned P450 enzymes in Mtb viability and patho-
genicity, it is important to investigate the physiological roles of the remaining P450s and to explore their potential 
involvement in bacterial physiology and survival in the host.
The identification of the first prokaryotic sterol demethylase (CYP51B1) in Mtb led to the proposal that azole 
antifungal drugs, which are effective, clinically-used inhibitors of fungal sterol demethylases, could be used as 
novel drugs for treating TB. The crystal structure of CYP51B1 was determined in complex with the antifungal 
drug fluconazole, revealing direct ligation of the P450 heme iron by a nitrogen atom from one of the inhibitor’s 
triazole rings. Although fluconazole is not very effective against Mtb15, the azole antifungals econazole and clo-
trimazole were found to be active against both latent and multidrug-resistant strains of Mtb in murine model sys-
tems8,21. However, the broad spectrum activity of these azole compounds has limited their application as systemic 
therapeutics. In addition to the potential of azole drugs as novel therapeutics against Mtb, they are also useful 
tools for probing the structure and function of the Mtb P450s8. Recently, Mtb CYP144A1, encoded by the H37Rv 
gene Rv177722,23, was identified to bind tightly to several azole antifungals, raising the possibility that this P450 
could be a target for novel anti-TB drug development.
In this paper, structural, biochemical, transcriptomic and bioinformatics data are presented to provide 
a detailed characterization of CYP144A1 and its potential as a Mtb drug target. The evolutionary ancestry of 
CYP144A1 is explored, and its conservation across the Mycobacterium genus is consistent with its importance to 
Mtb. Data from transcriptome annotation are reported, which reveal that alternative transcripts of CYP144A1 
are produced, leading to the production of different forms of the P450 protein. The expression and purifica-
tion of these different forms of CYP144A1 are described, as is the comparative analysis of their spectroscopic 
and ligand binding properties. Furthermore, the successful crystallization of the shorter form of CYP144A1 
(CYP144A1-TRV) and the first X-ray crystal structure of a CYP144A1 protein are reported, enabling novel 
insights into this enzyme, its active site organization and its relationship to other Mtb P450 enzymes.
Results and Discussion
Bioinformatics and evolutionary studies of CYP144A1. The Mtb gene Rv1777 (CYP144A1) from the 
pathogenic strain H37Rv (which encodes the cytochrome P450 enzyme CYP144A1) is located in a region of the 
Mtb genome rich in genes encoding proteins of unknown function. Thus, the prediction of the physiological 
function of CYP144A1 has been difficult from its genetic context alone22. The nearby gene Rv1771 encodes a 
L-gulono-1,4-lactone dehydrogenase shown to catalyse the final step required in L-ascorbic acid biosynthesis24, 
while the Rv1781c gene is predicted to encode a glucanotransferase enzyme (MalQ or amylomaltase)25,26. 
However, ligand-binding experiments with CYP144A1 using various sugars did not result in P450 heme spectral 
shifts that would be consistent with substrate-like binding (data not shown). The eccB5 and eccC5 genes (Rv1782 
and Rv1783) encode predicted components of the ESX-5 protein export system, related to the better known ESX-1 
virulence factor secretion system that exports the proteins ESX-1 (ESAT-6) and ESX-2 (CFP-10) into the host27. 
A little further downstream of CYP144A1 are the Rv1785c and Rv1786 genes, which encode the cytochrome P450 
CYP143A1 and a likely 3Fe-4S ferredoxin redox partner for the P450. A BLAST search using the Mtb CYP144A1 
protein sequence revealed that CYP144 P450s are highly conserved within Mtb strains (~99–100% identity), 
and also amongst the closely related Mtb complex (MTBC) members, which includes M. bovis (99%) and 
M. canettii (99%). Apparent orthologues of CYP144A1 occur in other pathogenic mycobacterial species, such as 
in M. marinum (80%) and M. ulcerans (79%), though typically with lower sequence identity to CYP144A1. The 
majority of species containing CYP144A1 orthologues are directly associated with a human disease, including 
M. colombiense (64% identity to Mtb CYP144A1), a member of the MAC (Mycobacterium avium complex) which 
can infect HIV patients with low CD4 cell counts28–31. CYP144A1 orthologues are also encoded by other myco-
bacteria isolated from patients with compromised immune systems (e.g. M. simiae, 76%; M. triplex, 80%; and 
M. lentiflavum, 76%). Among other CYP144A1-related sequences are CYP144A4 from the amphibian pathogen 
M. liflandii (77%), CYP144 orthologues from M. asiaticum (73%) which infects primates, and from the bacteria 
M. smegmatis (66%) and M. gastri (82%) which are typically considered to be non-pathogenic (Fig. 1).
No orthologues of CYP144 were observed outside the Mycobacterium genus to date. The apparent exclu-
sive conservation of CYP144 P450 family enzymes in the mycobacteria suggests the retention of an important 
catalytic role. In previous studies, the CYP144A1 gene was deleted from the Mtb H37Rv genome to investigate 
its effect on the growth and viability. It was found that the Mtb CYP144A1 deletion strain was viable and grew 
in vitro, but that the growth rate of the deletion strain was substantially lower than that of the wild-type Mtb 
H37Rv. In addition, the CYP144A1 deletion strain was markedly more susceptible to growth inhibition by azole 
drugs than the wild-type Mtb22. These data point to important function(s) for CYP144A1 in Mtb, and possi-
bly to its participation in the Mtb stress response mechanisms. Consistent with this conclusion is the finding 
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that CYP144A1 is among the mycobacterial genes induced following bacterial growth arrest with vancomycin32. 
Vancomycin inhibits Mtb cell wall synthesis, and thus a potential function for this P450 may be related to the 
stress response to cell wall damage.
Identification of a truncated form of the CYP144A1 P450 from transcriptome analysis. 
Analysis of the transcriptome from Mtb H37Rv identified a weak transcription start site (TSS) at genome position 
2010633, adjacent to a -10 consensus motif (TATTCT, 2010622-2010627) and 7 bp upstream from the annotated 
CYP144A1 Val1 start codon in Tuberculist23. There is near complete amino acid sequence identity between the 
predicted 434 amino acid residue Mtb H37Rv protein and the orthologues found in Mtb CDC1551, M. canetti 
CIPT, Mtb T46, and M. bovis AF2122/97. In previous studies, we expressed and purified this 434 amino acid 
full-length form of CYP144A1 (referred to hereafter as CYP144A1-FLV), demonstrating that it bound heme 
and displayed spectroscopic and ligand-binding properties consistent with a P45022. However, the best protein 
sequence alignments of Mtb CYP144A1 with many other mycobacterial CYP144 family P450 sequences are 
found using a sequence initiating at an internal residue around Met31. This highlighted the possibility that an 
alternative, shorter form of the Mtb CYP144A1 protein might be produced. Consistent with this model, Mtb 
H37Rv transcriptomics analysis identified a second, stronger TSS at position 2010745. The location of the second 
TSS would be consistent with the generation of a leaderless transcript with Met31 as the start codon. Interestingly, 
parallel studies of CYP144 transcripts from the Mtb N145 strains (a Beijing isolate similar to Mtb HN878) sug-
gest that this organism favours the upstream TSS (Fig. 2). Leaderless transcripts are common in Mtb33 and are 
characterized by the absence of a 5′ -untranslated region and a Shine-Dalgarno ribosome binding site. They are 
considered to comprise up to 25% of the transcripts in Mtb, suggesting that “truncated” versions of the numer-
ous proteins Mtb encodes might play crucial roles in mycobacterial physiology34. TSS mapping thus identified 
both “full-length” and “truncated” versions of CYP144A1 as potential translation products from alternative tran-
scripts. In light of these novel data, we generated plasmid expression constructs encoding both the full-length 
(CYP144A1-FLV) 434 amino acid protein and the 404 amino acid truncated version (CYP144A1-TRV) forms 
of CYP144A1. The expression and purification of the two forms of the CYP144A1 protein enabled comparative 
studies of their properties, and facilitated the crystallization of the proteins in order to obtain the first structural 
data for Mtb CYP144A1.
Expression and purification of CYP144A1 in its truncated and full-length forms. The N-terminal 
truncated version construct of CYP144A1 (CYP144A1-TRV) was generated using the previously prepared 
full-length version CYP144A1-FLV/pET15b plasmid vector22, and by deletion of the region encoding the first 30 
amino acids. The CYP144A1-TRV construct initiated from the first methionine codon (Met31) of the CYP144A1 
gene, corresponding to the second of the two CYP144A1 TSS detected (Fig. 3A). CYP144A1-FLV and TRV were 
both expressed and purified as His6-tagged constructs in E. coli as described in the Materials and Methods. Both 
the CYP144A1-TRV and CYP144A1-FLV forms were readily purified using nickel affinity, anion exchange and 
Figure 1. Phylogenetic tree illustrating the evolutionary relationship of CYP144A1 to other mycobacterial 
CYP144 family P450s. Protein sequence alignment of CYP144A1 was made with CYP144 sequences from 
other mycobacteria. Protein sequence conservation between the CYP144 proteins in all species ranges from 
58–100%, with higher conservation of CYP144A1 sequence identity within the Mtb complex (MTBC), and the 
lowest conservation in the M. avium complex (MAC). The 0.05 reference scale marks a 5% estimated sequence 
variance. The figure was generated using MEGA644.
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size exclusion column chromatography steps. Both forms of the enzyme were soluble, indicating that the enzyme 
is almost certainly cytosolic in Mtb. This is characteristic for the majority of the Mtb P450s characterized to date, 
including the cholesterol oxidizing CYP125A1 and CYP142A1 enzymes, the branched chain fatty acid hydroxy-
lase CYP124A1 and the cyclodipeptide oxidase CYP121A17,11,13,16–18. A notable exception is CYP128A1, a likely 
dihydromenaquinone hydroxylase, which may be membrane associated in order to enable access to its lipo-
philic dihydromenaquinone substrate(s) that are retained in the Mtb cell membrane14. The CYP144A1-FLV and 
CYP144A1-TRV proteins were purified and shown to have approximate masses of 49 kDa and 46 kDa, respec-
tively, as observed by SDS-PAGE analysis (Fig. 3B). The different masses of the two CYP144A1 forms were con-
firmed using electrospray ionization mass spectrometry, with a mass of 49251 Da determined for CYP144-FLV 
and 46008 Da for CYP144-TRV (Fig. 3C,D). These values are consistent with the expected masses from the amino 
Figure 2. Alternative transcripts of the CYP144A1 gene produced by Mtb H37Rv. The figure shows that two 
alternative transcriptional start sites (TSS) are located at nucleotides 201063 (CYP144A1-FLV) and 2010745 
(CYP144A1-TRV) in the Mtb H37Rv genome. These are shown as blue lines in the figure. A higher level of 
transcription occurs for the CYP144A1-TRV version of the gene. TSS are demarcated by black rectangles 
and show detailed views of the regions around the TSS for the two forms of the gene, identifying the relevant 
regulatory regions and the start codons (Val1 and Met31, respectively) for CYP144A1-FLV (VRRSPK… ) and 
CYP144A1-TRV (… MTIAKD… ).
Figure 3. Expression and purification of CYP144A1-FLV and CYP144A1-TRV. Panel (A) shows the genetic 
truncation of the intact CYP144A1-FLV (red) to form CYP144A1-FLV – removing the gene segment encoding 
residues Va11 to Leu30, shown with the CYP144A1-FLV (Val) and -TRV (Met) initiator residues in yellow 
circles. This produces the CYP144A1-TRV (grey), with 30 amino acids fewer than CYP144A1-FLV (red). Panel 
(B) shows purification and approximate molecular weight determination of CYP144A1-FLV and -TRV by 
SDS-PAGE analysis, with markers of indicated mass (kDa) in the first lane. Panels (C,D) show accurate mass 
spectra of CYP144A1-FLV (49251 Da) and CYP144A1-TRV (46008 Da) obtained by high-resolution mass 
spectrometry under denaturing conditions using 40 μ M protein in both cases.
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acid sequences of the respective forms of the His6-tagged CYP144A1 proteins, minus the initial methionine resi-
due (CYP144A1 gene and protein sequences are shown in Supplementary Figure S1), and are also consistent with 
our previous studies of CYP144-FLV22.
UV-Visible spectroscopic properties of CYP144A1-FLV and CYP144A1-TRV. UV-Visible 
(UV-Vis) spectroscopy is a valuable method for characterizing P450s and for the quantitative analysis of their 
ligand-binding properties. The UV-Vis spectral features of the FLV and TRV forms of CYP144A1 were found to 
be identical for the two proteins in their oxidized and reduced states, and for these proteins bound to the gase-
ous ligands nitric oxide (NO, in the ferric form) and carbon monoxide (CO, in the ferrous form). As such, only 
UV-Vis spectral data for the newly constructed CYP144A1-TRV form are presented (Fig. 4A). The consistency 
in the spectral properties of the two CYP144A1 proteins suggests that the 30 amino acid N-terminal “extension” 
on CYP144A1-FLV does not influence the environment of the heme prosthetic group or the coordination of its 
heme iron. The oxidized form of CYP144A1-TRV has a Soret peak at 420 nm, which is slightly red-shifted in com-
parison to the resting ferric states of other characterized Mtb P450s, such as CYP121A1 at 416.5 nm13, CYP51B1 
at 419 nm15, and CYP130A1 at 418 nm35.
The CYP144A1-TRV resting state Soret peak of 420 nm is consistent with that reported previously by Driscoll 
et al.22 for CYP144A1-FLV (420.5 nm). Both the FLV and TRV forms of the CYP144A1 enzyme were dialy-
sed extensively (~12 hours) after the nickel-IDA affinity chromatography step of protein purification to ensure 
the removal of any residual imidazole (used to elute the P450s from the nickel column) that remained bound 
to the heme iron. The affinity for imidazole is weak (with a Kd of 3.0 mM for the CYP144A1-FLV form22) and 
so this precautionary step should effect near-complete removal of the ligand. Thus, the 420 nm Soret peak for 
CYP144A1-TRV almost certainly reflects accurately the properties of the P450 protein in its ferric, low-spin 
(LS) state, with water as the 6th ligand to the heme iron. The ferric NO-bound CYP144A1-TRV complex showed 
distinct absorbance properties, with the Soret peak at 437 nm and major spectral changes in the alpha/beta band 
region with maxima at 576 nm and 544 nm. These features are consistent with those of the NO complexes of the 
aforementioned Mtb P450s CYP51B1, CYP130A1 and CYP121A19,13,15. The ferrous CO-bound CYP144A1-TRV 
produced a Soret peak at 420 nm, and thus forms almost completely the cysteine thiol-coordinated (P420) spe-
cies. Only a minor peak for the cysteine thiolate-coordinated P450 species was detected at 448 nm. The consist-
ency in the UV-Vis spectral properties of CYP144A1-FLV and -TRV in their aqua-ligated ferric, ferric-NO and 
ferrous-CO complexes provides further evidence that the 30 amino acid N-terminal truncation made to generate 
the CYP144A1-TRV protein does not alter its heme environment significantly22.
EPR spectroscopic analysis of the CYP144A1-FLV and CYP144A1-TRV proteins. Electron para-
magnetic resonance (EPR) X-band spectra were recorded for the oxidized (ferric) CYP144A1-FLV and -TRV pro-
teins to provide further insights into the heme ligation environment and spin-state equilibrium in the two forms 
of CYP144A1. Spectra for both the FLV and TRV CYP144A1 proteins were similar, with g-values of gz = 2.41, 
gy = 2.24, and gx = 1.92 (2.41/2.24/1.92) in both cases (Fig. 4B). These data are indicative of a predominantly 
low-spin ferric and cysteinate-coordinated heme iron. No detectable signals for a ferric high-spin species were 
detected. The low-spin state of both forms of CYP144A1 is consistent with previous work on the CYP144A1-FLV 
P450 (g-values of 2.42/2.25/1.93), and these g-values are also similar to those for other Mtb P450s in their 
low-spin states, including the cholesterol hydroxylase CYP142A1 and the cyclodipeptide oxidase CYP121A17,20. 
The EPR spectrum of the CYP144A1-TRV protein bound to the azole drug econazole also shows the complete 
retention of a low-spin state of the enzyme, but with altered g-values of 2.43/2.25/1.90 (Fig. 4B). Econazole binds 
tightly to the CYP144A1-FLV protein (Kd = 0.78 ± 0.29 μ M), and an optical titration of CYP144A1-TRV with 
econazole also revealed a similar Kd value (0.72 ± 0.18 μ M). Econazole binding to CYP144A1-TRV occurs with 
Figure 4. Spectroscopic properties of CYP144A1–TRV. Panel (A) UV-visible absorbance spectra of ligand-
free CYP144A1-TRV (6 μ Μ , black line), nitric oxide-bound (red line) and reduced/carbon monoxide-bound 
forms (blue line). The Soret spectral maxima are at 420 nm, 437 nm and 420 nm, respectively. Panel (B) X-band 
EPR spectra of ligand-free and econazole (400 μ Μ )-bound CYP144A1-TRV (200 μ Μ ), with the g-values 
labelled.
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a heme Soret red shift to 423 nm, which is again similar to that seen for CYP144A1-FLV (Soret Amax of the 
CYP144A1-FLV/econazole complex is at 424 nm). The EPR g-values for the CYP144A1-FLV/econazole complex 
are at 2.45/2.26/1.8922. These data are further confirmatory that the CYP144A1-TRV truncation does not influ-
ence the P450 heme environment significantly by comparison with the CYP144A1-FLV enzyme (Fig. 4B).
In the econazole complexes of the CYP144A1 enzyme forms, it might be expected that the gz (and gx) val-
ues would be more substantially changed from those in the resting, aqua-coordinated state if there was direct 
coordination of the heme iron by an econazole imidazole nitrogen (e.g. to gz ~2.50 or beyond). Indeed, in pre-
vious studies of the CYP144A1-FLV protein a minor gz feature at 2.62 was observed that might indicate direct 
coordination of the heme iron by an econazole nitrogen in a small proportion of this P450 form22. However, 
the relatively small changes observed in the EPR spectra for the CYP144A1-TRV/FLV proteins may indicate 
that econazole ligates the heme iron indirectly. This could occur via a retained 6th ligand water molecule in the 
majority of the P450 molecules for both these proteins. A similar phenomenon was reported for CYP121A1 
in complex with fluconazole, and confirmed by X-ray crystallographic data36. In this case, the g-values for the 
CYP121A1-fluconazole complex are 2.45/2.26/1.90, compared to 2.48/2.25/1.90 in the resting form. A similar 
conclusion can be drawn from the rather less extensive Soret shift of the CYP144A1-FLV/TRV proteins on bind-
ing econazole (420.5/420 nm to 424/423 nm) than is observed typically in other P450s (e.g. from 416.5 nm to 
423 nm on the binding of econazole to CYP121A1)20,37.
Differential Scanning Calorimetry (DSC) studies on the CYP144A1-FLV and CYP144A1-TRV 
enzyme forms. DSC was used to analyse the thermal stability of both the CYP144A1-FLV and -TRV pro-
teins, in order to probe for any differences induced by truncation of the enzyme. The thermal unfolding profiles 
for both enzymes indicated a single unfolding midpoint temperature (Tm value) at 47 °C (Fig. 5A), confirming 
that the N-terminal truncation did not alter the thermal stability of the CYP144A1-TRV significantly. Further 
comparative analyses of the thermal stability of the clotrimazole- and econazole-bound forms of CYP144A1 again 
yielded highly similar results for the CYP144A1-FLV and -TRV proteins. The binding of clotrimazole or econa-
zole increased the Tm for both forms of the protein to 50 °C, indicating that the tight-binding azoles stabilize both 
forms of CYP144A1 to similar extents (Fig. 5B,C). The similarity in thermal stability of both CYP144A1 forms 
in their ligand-free and azole drug-bound states again indicates that the stability of the CYP144A1-TRV protein 
is not compromised by the deletion of the 30 amino acid N-terminal segment, and suggests that this part of the 
protein is not integral to the folding or stability of the structural core of the P450.
Crystal structure determination of CYP144A1-TRV. Crystallization of both the FLV and TRV forms 
of CYP144A1 was achieved, producing crystals with a similar bipyramidal morphology and size (100 μ m) in each 
case. CYP144A1-TRV crystals diffracted to a resolution of 1.55 Å and a ligand-free crystal structure of this form 
of the CYP144A1 protein was successfully solved using molecular replacement with the Mtb cholesterol oxidase 
enzyme CYP142A1 (PDB 2XKR) as a search model38. The CYP144A1-FLV crystals yielded a similar structure 
(data not shown), with no electron density visible for the additional N-terminal amino acids. This could either 
reflect that proteolytic cleavage of the N-terminal region of the CYP144A1-FLV form had occurred, or else be 
due to the fact that the 30 additional N-terminal residues present in CYP144A1-FLV are largely unstructured. 
Analysis of the CYP144A1-FLV protein sequence using the protein disorder prediction system (PrDOS)39 algo-
rithm indicated a disorder probability nearing 90% for these 30 amino acids (Fig. 6A).
The CYP144A1-TRV crystal structure contains two monomers in the asymmetric unit. However, a dimeric 
solution state is unlikely, since solution state MALLS experiments (Fig. 6B,C) indicated that both the FLV and 
TRV forms of CYP144A1 are soluble, monomeric proteins (as are the majority of bacterial P450s). Both mono-
mers in the crystal asymmetric unit have a similar overall conformation, with an rmsd of 0.55 Å for 393 C alpha 
atoms. The three dimensional structure and secondary structural organization of CYP144A1-TRV resembles 
those of previously solved Mtb P450 structures, and is most similar to P450 CalO2 (PDB 3BUJ), a P450 involved 
in biosynthesis of the enediyne antitumor antibiotic calicheamicin40 (Z score 16.1, rmsd 1.96 Å for 346 C alpha 
Figure 5. Differential Scanning Calorimetry (DSC) analysis of CYP144A1-TRV. Panels (A–C) show DSC 
thermograms for ligand-free, econazole-bound (30 μ Μ ), and clotrimazole-bound (30 μ Μ ) forms of CYP144A1-
TRV (8 μ Μ ), respectively. The collected data (thick black line) and fitting (dotted line) are shown in each case. 
The Tm values are at 47 °C, 50 °C and 50 °C, respectively.
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atoms), and to the Mtb cholesterol hydroxylase CYP142A1 (PBD code 2YOO) (Z score 15.9, rmsd 1.93 Å for 356 
C alpha atoms) (Fig. 7B,C)7,38.
The structural elements (F/G-helices and BC-loop region) important in determining active site access and 
substrate specificity41 are those that are most distinct in CYP144-TRV from other P450 structures (Fig. 7A). The 
relatively long linker region connecting the B-and C-helices folds into an extended beta-hairpin, that occupies the 
region between the N-terminal beta-sheet and the FG-loop. This creates a large access channel to the heme cavity 
Figure 6. Protein disorder prediction and hydrodynamic features of CYP144A1. Panel (A) Protein disorder 
prediction analysis of CYP144A1-FLV (red), CYP144A1-TRV (green) and the Mtb cholesterol hydroxylase CYP142A1 
(blue). The threshold (black line) measure of the prediction’s false positive rate was set at 5%. The numbers of 
disordered amino acids in the protein sequence are indicated on the top panel. The figure was generated using PrDOS 
software39. Panels (B,C) Multiangle Laser Light Scattering (MALLS) analysis of CYP144A1-TRV and CYP144A1-FLV, 
respectively. The refractive index (RI) data are shown as black lines in both cases, with the blue lines indicating the 
apparent molar mass of the relevant proteins. The data are consistent with both forms of CYP144A1 being monomeric 
in solution, and having molar masses of ~46,000 g/mol (CYP144A1-TRV) and ~49,000 g/mol (CYP144A1-FLV).
Figure 7. The crystal structure of CYP144A1-TRV. Panels (A,D) Ribbon and surface representations, 
respectively, of the Mtb P450 CYP144A1-TRV. The heme, BC-loop, FG-helices and I-helix are coloured red, 
blue, dark red and yellow, respectively. Panels (B,C) Ribbon structure representations of Mycobacterium 
smegmatis CYP142A2 (PDB 2YOO) and the putative orsellinic acid oxidase P450 CalO2 (PDB 3BUJ) using 
similar colour coding as panel (A). The orientation of both structures is similar to that of CYP144A1-TRV in 
panel (A). Panel (E) Active site structure of CYP144A1-TRV, with key residues colour coded as in panel (A). 
Panels (A–E) were generated using PyMOL48.
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(Fig. 7D), approximately 10 Å deep from the protein surface and 10 Å wide. This suggests the binding of relatively 
large substrates in CYP144A1.
The active site of CYP144A1-TRV is predominantly hydrophobic, with Phe321 and His324 side chains located 
in close proximity of the heme 6th ligand. These residues are likely to be important in determining substrate selec-
tivity (Fig. 7E). I-helix residues Glu277 and Ser268 are probably required for protonation of P450 heme iron-oxo 
species during catalysis. While CYP121A1 also has a serine residue corresponding to Ser268 in CYP144A1-TRV, 
other Mtb P450s use a threonine7,9,11,15–17. However, there are few other similarities in the amino acid composition 
of the active site of CYP144A1 compared to those of the other structurally characterized Mtb P450s, suggesting 
a unique role and substrate selectivity profile for CYP144A1. The substantial structural differences between the 
active site organization in CYP144A1 and those of the other Mtb P450 isoform structures should enable the 
design of CYP144A1 isoform-selective inhibitors, a topic addressed in our ongoing fragment screening studies 
of this enzyme.
Conclusions
There is growing recognition that alternative transcriptional start sites and leaderless transcripts play an impor-
tant role in increasing the diversity of proteins produced from microbial genomes, with around 25% of mycobac-
terial transcripts being leaderless34. In the case of the M. tuberculosis cytochrome P450 CYP144A1, annotation 
of the relevant P450 (CYP) gene in the Tuberculist database indicates that the encoded protein has 434 amino 
acids with a valine as the first residue (from a GTG codon). Previous studies indicated that this full length form 
of CYP144A1 (CYP144A1-FLV) could be purified using an E. coli expression system22. However, a methionine 
is also located at residue 31 in the CYP144A1-FLV form of the P450, and this was considered as an alterna-
tive initiation codon for the protein, particularly in light of the predicted “truncated version” of CYP144A1 
(CYP144A1-TRV) being only 404 amino acids in length – a size closer to the norm for a typical prokaryotic 
P4506. Further studies from transcriptomics analysis resulted in the identification of an internal transcriptional 
start site from a leaderless transcript producing the CYP144A1-TRV form. Both the FLV and TRV forms of the 
CYP144A1 protein were successfully expressed and purified to homogeneity. Biophysical and biochemical studies 
revealed similar properties for the two proteins forms, confirming that the 30 N-terminal amino acid residues 
that were removed in the CYP14A1-TRV form did not affect protein stability, oligomerization state or heme envi-
ronment. However, bioinformatics studies indicated that the N-terminal 30 amino acid region of CYP144A1-FLV 
was mainly disordered and that this might explain problems associated with the structural resolution of this 
region in the crystal structure of the CYP144A1-FLV form of the P450. Consistent with this conclusion, it was 
found that the CYP144A1-TRV form crystallized readily, allowing the determination of a high resolution (1.55 Å) 
X-ray structure of the ligand-free CYP144A1-TRV enzyme. This crystal structure shows a P450 with a large and 
predominantly hydrophobic active site, suggesting that CYP144A1’s natural substrate(s) are bulky hydrophobic 
molecules. These data provide the basis for biochemical and modelling studies to identify substrates and other lig-
ands for the P450. In this respect, our ongoing work involves fragment based screening studies to identify novel, 
specific ligands for CYP144A1 that can be developed into useful reagents for use as inhibitors and as mechanistic 
probes of this Mtb P450.
Methods
Bioinformatics studies. All protein sequence alignments were performed using the Phylogeny web tool and 
the NCBI BLAST program42,43. The individual protein sequences for the CYP144A1-FLV and CYP144A1-TRV 
P450s were interrogated on the database in searches for sequence neighbours. The resulting output sequences for 
the various species were further aligned and saved in CLUSTALW format. The phylogenetic tree was generated 
using MEGA6 software44. The aligned CLUSTALW format sequences were imported into the MEGA6 phylogeny 
tool and a phylogenetic tree was generated using the “construct/test maximum likelihood” method. Structural 
alignments were performed using the ESPript web tool45.
Identification of CYP144A1 transcriptional start sites. Transcriptional start sites (TSSs) for 
CYP144A1 were mapped at single-base resolution by sequencing of a preparation of RNA from an exponential 
culture of M. tuberculosis H37Rv after enrichment for transcripts with intact 5′ triphosphate ends, as described 
by Cortes et al.33.
Cloning of the CYP144A1-FLV and TRV genes. The pCYP144A1-FLV construct encoding the 
full-length (434 amino acid) recombinant Mtb CYP144A1-FLV enzyme was produced as previously described22. 
The truncated Rv1777 gene encoding CYP144A1-TRV was generated by PCR from a previously cloned con-
struct of the full length Rv1777 gene in the pET15b plasmid vector using the forward primer, 5′ -CGATCACG 
CTGAACATATGACAATTGCC-3′ and the reverse primer, 5′ -GGCAATTGTCATATGTTCAGCGTGATCG-3′ 
(Merck-Millipore, Watford UK). The underlined letters in both the forward and reverse primers indicates an 
engineered NdeI restriction endonuclease site. The bold letters in the forward primer indicate the start codon 
ATG. The PCR amplification reaction was carried out in a Techne TC-512 thermal cycler (Techne, Cambridge 
UK) using the proofreading Pfu Turbo DNA polymerase (Agilent, Cheadle UK). The amplification conditions 
were 95 °C for 2 min, 20 cycles of 95 °C for 30 s, 60 °C for 30 s, and 68 °C for 7 min. The PCR reaction was followed 
by a final polymerization step of 68 °C for 7 min. The generation of the truncated gene encoding CYP144A1-TRV 
was achieved by removing the DNA segment between the two NdeI restriction sites through a NdeI endo-
nuclease digest reaction, followed by re-circularization carried out using a Quick Ligation Kit (NEB, Hitchin 
UK) to produce the pCYP144A1-TRV construct. The resulting CYP144A1-TRV gene construct encodes the 
CYP144A1-TRV protein with the initial 30 amino acids from the intact CYP144A1-FLV protein deleted.
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Expression and purification of the CYP144A1-FLV and CYP144A1-TRV forms of CYP144A1. 
CYP144A1-FLV and CYP144A1-TRV proteins were produced by transforming the E. coli strain C41 (DE3) 
(Merck-Millipore, Watford UK) with the pCYP144A1-FLV or pCYP144A1-TRV plasmid constructs. Expression 
of the relevant gene constructs was done using the isopropyl β -D-thiogalactopyranoside (IPTG)-inducible T7 
RNA polymerase/promoter system. This was achieved through IPTG-dependent expression of the T7 RNA poly-
merase from a chromosomally integrated gene copy in the C41 (DE3) strain, leading to T7 polymerase-dependent 
transcription of the CYP144A1-FLV and -TRV genes in pET15b. CYP144A1 protein production was typically 
done in ~15 litre cultures of 2xYT growth medium (ForMedium, Hunstanton UK). The culture medium was dis-
tributed between 24 × 2 litre conical flasks. Each flask contained 600 ml of growth medium and ampicillin (50 μ 
g/ml), and was inoculated with 6 ml of transformant cells from an overnight culture in the same medium under 
the same conditions. Cells were grown at 37 °C with agitation (200 rpm) until an OD600 of 0.5 was reached, and 
then the growth temperature was decreased to 22 °C and bacterial cell growth was continued to an OD600 of 0.7. 
100 μ M IPTG was then added to induce target gene expression, along with 100 μ M delta-aminolevulinic acid (Δ 
ALA) to promote heme synthesis and incorporation into the proteins. The transformant cells were then grown 
for a further 36 h. The cells were harvested by centrifugation at 6000 g for 10 min at 4 °C using a JLA-8.100 rotor 
in an Avanti J-26 XP centrifuge. The supernatant was discarded and cell pellets were resuspended in ~300 ml of 
ice cold 50 mM potassium phosphate (KPi, pH 8.0) containing 250 mM NaCl and 10% glycerol. The protease 
inhibitors phenylmethanesulfonyl fluoride (PMSF, 1 mM), benzamidine hydrochloride (1 mM) and six cOmplete 
EDTA-free tablets (Roche Diagnostics Ltd, West Sussex UK) were added to inhibit protease enzymes. The cells 
were lysed on ice by ultrasonication (Bandelin Sonopuls sonicator) with 6 cycles of 30 s on and 60 s rest periods. 
The cell lysate was centrifuged at 40,000 g for 45 min at 4 °C and the supernatant collected.
The supernatant was loaded onto a Ni-IDA column (Generon, Maidenhead UK) pre-equilibrated with 50 mM 
KPi (pH 8.0) loading buffer containing 250 mM NaCl and 10% glycerol, using a peristaltic pump (GE Healthcare, 
Little Chalfont UK). The column was washed with ~80 ml of loading buffer and the flow-through discarded. 
Proteins were eluted from the column by washing consecutively with increasing concentrations of imidazole 
[10 mM (250 ml), 80 mM (150 ml) and 160 mM (100 ml) in the loading buffer]. Each eluted fraction was ana-
lysed spectrally (250–800 nm), and by SDS-PAGE. Fractions containing relatively pure (mainly the 80 mM and 
160 mM) CYP144A1 samples were pooled and concentrated to ~100 ml using ultrafiltration with Amicon con-
centrators (Merck-Millipore) at 4 °C. The concentrated protein was further dialysed into 50 mM Tris HCl (pH 
7.2, dialysis buffer) containing 50 mM KCl and 1 mM EDTA to remove excess imidazole. The dialysed protein 
was then loaded onto a Q-Sepharose column (10 cm × 4 cm) pre-equilibrated with the dialysis buffer, and then 
washed and eluted with linear gradient of KCl (50–500 mM) in the dialysis buffer using an automated AKTA puri-
fication system (GE Healthcare). Fractions were analysed both spectrally and by SDS-PAGE as before. Samples 
with high A420/A280 (or Reinheitszahl, Rz) ratios (≥ 1) were pooled and concentrated to ~200 μ l by ultrafiltration 
using a Centriprep 30 concentrator (Merck-Millipore) at 1500 g. The concentrated protein was further dialysed 
into 10 mM Tris HCl (pH 7.5) containing 150 mM NaCl. The protein was then subjected to a final purification 
step via Sephacryl S-200 size exclusion chromatography column using an AKTA purification system. Fractions 
were again analysed both spectrally and by SDS-PAGE. Fractions with Rz values of ≥ 1.5 were pooled and concen-
trated as before, and dialysed into 50 mM Tris.HCl, pH 7.5 containing 50 mM NaCl and 20% glycerol, and stored 
at − 80 °C until use. Purity of the CYP144A1 proteins was assessed by both SDS-PAGE and UV-Vis spectroscopy, 
with SDS-PAGE samples migrating as a single band at the appropriate molecular weight on SDS-PAGE gels and 
having an Rz ratio of ≥ 1.5 being considered as pure.
Mass spectrometry. Protein solutions for mass spectrometry (40 μ M) were prepared by dilution of purified 
proteins (500–1000 μ M) in 200 μ M ammonium acetate buffer, pH 7.0. Liquid chromatography-mass spectrom-
etry (LC–MS) was performed on a Xevo G2-S Q-TOF UPLC instrument (Waters, Elstree UK) coupled to an 
Acquity UPLC system. Samples were eluted through an Acquity UPLC BEH300 C4 column (1.7 μ m, 2.1 × 50 mm) 
using a mobile phase of Solvent A: water with 0.1% formic acid, and Solvent B: 95% acetonitrile containing 0.01% 
formic acid. The elution gradient was run using 95% Solution A for 5.21 minutes, 100% Solution B for 1 minute, 
and 100% Solution A for 1 minute at a flow rate of 0.2 ml min−1 over a total run time of 7.29 minutes. The electro-
spray source was operated with a capillary voltage of 2.0 kV and a cone voltage of 40 V. Nitrogen was used as the 
desolvation gas at a total flow of 850 litres hr−1. Data acquisition and processing was performed using Micromass 
MassLynx v4.1 software with total mass spectra reconstructed from the ion series using the pre-installed MaxEnt 
algorithm.
Determination of molecular weight and aggregation state of CYP144A1-FLV and CYP144A1-TRV 
by multi-angle laser light scattering (MALLS). An estimate of the molecular weight of both CYP144A1-FLV 
and CYP144A1-TRV proteins, as well as analysis of their aggregation states, was obtained using a MALLS 
detector (Wyatt DAWN Eos, Haverhill UK). This was immediately preceded by passing the sample through a 
Superdex 200 gel filtration step integrated into the detector (24 ml S200 10/300 GL, GE Healthcare). The column 
was run at a flow rate of ~0.8 ml/min, using 100 μ l samples of 2 mg/ml CYP144A1 enzymes in 10 mM Tris.HCl 
buffer (pH 7.5) containing 150 mM NaCl. An Optilab rEX and Quasi Elastic Light Scattering (QELS) apparatus 
(both from Wyatt) were used to obtain the refractive index and the hydrodynamic radius of CYP144A1 enzymes, 
respectively. A K5 cell type and a laser wavelength of 690 nm were used to collect data at 1 s intervals.
EPR spectroscopic analysis of CYP144A1. Continuous wave X-band electron paramagnetic resonance 
(EPR) spectra of CYP144A1 proteins were obtained at 10 K using a Bruker ELEXSYS E500 EPR spectrome-
ter equipped with an ER 4122SHQ Super High Q cavity. Temperature control was effected using an Oxford 
Instruments ESR900 cryostat connected to an ITC 503 temperature controller. Microwave power was 0.5 mW, 
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modulation frequency was 100 KHz and the modulation amplitude was 5 G. EPR spectra were collected for the 
CYP144A1-FLV and CYP144A1-TRV proteins in the ligand-free state (200 μ M) and at the same protein concen-
tration following the addition of the azole inhibitor drug econazole (400 μ M).
Determination of CYP144A1 thermal stability by Differential Scanning Calorimetry (DSC). 
DSC Experiments were performed using a Microcal VP-DSC instrument (Malvern Instruments, Malvern UK). 
Parameters used for running samples were 20–80 °C temperature gradient, 10 min prescan thermostat and a 
90 °C/h scan rate. Baseline scans were performed using assay buffer (10 mM KPi, 100 mM NaCl, pH 7.0) and pro-
teins were near-saturated with the azole ligand clotrimazole and econazole prior to DSC analysis of ligand-bound 
samples. All samples were run using 8 μ M protein and azole ligands were used at concentrations at least 20x those 
of the protein and according to the affinity for the azoles. Data analysis was performed using Origin Software 
(OriginLab, Northampton MA).
CYP144A1 crystallization and structure determination. Crystallization was performed using the sit-
ting drop method using 20 mg/ml CYP144A1. Drops were prepared by the addition of 0.2 μ l of CYP144A1-FLV 
and -TRV proteins to 0.2 μ l of mother liquor, and by incubating at 4 °C. Following initial crystallogenesis using 
commercial screens, crystallization conditions were further refined using the sitting drop vapour diffusion tech-
nique to 0.8 or 1.0 M (NH4)2SO4 with 0.1 M HEPES, pH 7.55, and 25% PEG 3350. Single crystals were flash cooled 
after addition of 10% PEG 200 as cryoprotectant, and data were collected at Diamond synchrotron beamline IO3 
(Harwell, UK). The CYP144A1-TRV structure (PDB 5HDI) was solved by molecular replacement with the M. 
tuberculosis CYP142A1 structure (PDB 2XKR) as the template. Following automatic model building and refine-
ment using Buccaneer from the CCP4 suite46, the model was completed using iterative rounds of refinement using 
Refmac5 intercalated with manual model building using COOT47. Data collection and refinement parameters for 
the CYP144-TRV crystal structure are presented in Table 1.
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